True, but I&#x27;d say that the unreliability of blood testing as a diagnostic technique is extremely pertinent information for investors to have when investing in a company that is built on blood testing as a diagnostic technique. My point is just that it&#x27;s surprising that the journalist for this story appears to have spent more time researching the subject for this article than the investors putting in ~$700M.